Avacta Group (AVCT)

 

AVCT Share PerformanceMore

52 week high103.95 22/09/16
52 week low60.00 31/03/17
52 week change -26.31 (-26.31%)
4 week volume625,860 25/08/17

Media for (AVCT)

Presenter: Dr. Alastair Smith
01/08/2014
Presenter: Dr. Alastair Smith
07/05/2014

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Notice of Results

RNS Number: 0204Q Avacta Group PLC 07 September 2017 07 September 2017 Avacta Group plc ("Avacta", the "Group" or the "Company") Notice of Results Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and research reagents, will announce its financial results for the year ended 31 July 2017 on Wednesday, 4 October 2017. Enquiries: Av...

Director Deals - Avacta Group PLC (AVCT)

Prof Alastair Smith, Chief Executive Officer, bought 33,225 shares in the company on the 21st August 2017 at a price of 74...

Director/PDMR Shareholding

RNS Number: 5552O Avacta Group PLC 21 August 2017 21 August 2017 Avacta Group plc ("Avacta", the "Group" or the "Company") Director/PDMR Shareholding Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and research reagents, announces that its Chief Executive Officer, Dr Alastair Smith has today purchased 33,225 ordinary share...

Avacta revenues rise

Avacta Group expects revenues for the year ended 31 July to be 27% up on last time at 2.75m, in line with market forecasts...

Trading Update

RNS Number: 2177N Avacta Group PLC 07 August 2017 07 August 2017 Avacta Group plc ("Avacta" or "the Group" or "the Company") Trading Update and Notice of Results Significant progress and substantial de-risking of the Affimer therapeutics platform Commercial traction for Affimer reagents building and multiple licenses agreed Avacta Group plc (AIM: ...

Issue of Equity

RNS Number: 5893M Avacta Group PLC 31 July 2017 31 July 2017 Avacta Group plc ("Avacta", the "Company" or the "Group") Issue of Equity Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and research reagents, today announces that following the exercise of employee share options it has issued and allotted 500 new ordinary shares of 10...

Director/PDMR Shareholding

RNS Number: 4617M Avacta Group PLC 28 July 2017 28 July 2017 Avacta Group plc ("Avacta" or "the Group" or "the Company") Director/PDMR Shareholding Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and research reagents, announces that its Chief Executive Officer, Dr Alastair Smith has today transferred 87,850 ordinary shares...

Director Dealing and Issue of Equity

RNS Number: 1232K Avacta Group PLC 05 July 2017 05 July 2017 Avacta Group plc ("Avacta" or "the Group" or "the Company") Director Dealing and Issue of Equity Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and research reagents, announces that application has been made for 4,345 new ordinary shares of 10p each (the "New Ordi...

Fundamental DataMore

EPS-6.86
Dividend yield0 %

Equity Research (AVCT)

hardman & co
Avacta Group Plc
24/05/2017
Avacta is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody...
hardman & co
Avacta Group Plc
08/05/2017
Avacta is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody...
hardman & co
Avacta Group Plc
12/04/2017
Avacta is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody...

Latest discussion posts More

  • Re: Moderna

    comment 060917 http://www.ft.com/content/ab138504-8c2e-11e7-a352-e46f43c5825d mol
    9-Sep-2017
    mol42
  • Re: faster deeper smaller...

    The problem for Avacta is summed up by the statement ?There?s a whole zoo of non-anti-body scaffolds out there,?
    22-Aug-2017
    Proverbs 26 vs 5
  • FT comment

    180817 While AstraZeneca has suffered a serious setback in the hot field of cancer immunotherapy, a host of comparative minnows, undeterred, are pressing ahead with allied ...
    21-Aug-2017
    mol42

Users' HoldingsMore

Users who hold Avacta Group also hold..
LLOYDS GRP.18%
ROCKHOPPER16%
AFC ENERGY12%
ROYAL BANK SCOT12%
BARCLAYS12%

Codes & Symbols

ISINGB00BYYW9G87
SymbolsAVCT, LSE:AVCT, AVCT.L, AVCT:LN, LON:AVCT, XLON:AVCT